Loading organizations...
§ Venture Capital · Boston, MA, USA
Venture capital firm investing in deep tech and deep science companies, focused on commercializing scientific breakthroughs.
Ahren Innovation Capital is a venture capital firm based in Cambridge and London in the United Kingdom, that specializes in deep technology and scientific breakthrough investments from the pre-seed through pre-IPO stages. The institution provides capital and operational support to early-stage companies operating across sectors such as artificial intelligence, biotechnology, quantum computing, and clean energy. The firm currently manages over $800 million in assets under management, following the $250 million close of its first fund in 2019 and the subsequent close of its second fund in May 2024. Its investment portfolio features several science and technology startups, including AI21 Labs, Graphcore, ZOE, and Zapata Computing. The firm's partners have previously created commercial technologies that reached a combined valuation exceeding $100 billion. Ahren Innovation Capital was founded in 2017 by Alice Newcombe-Ellis, alongside Andy Parker, Gregory Winter, and Lord Martin Rees.
Key people at Ahren Innovation Capital.
Ahren Innovation Capital is a venture investment firm founded in 2017, headquartered in Cambridge, UK, that focuses on backing transformational companies at the intersection of deep technology and deep science. Its mission is to provide smart, patient, and active capital to visionary founders developing breakthrough technologies in sectors such as Brain & AI, Genetics & Platform Technologies, Space & Robotics, and Efficient Energy. The firm invests across stages from pre-seed to pre-IPO, aiming to create or penetrate massive markets by taking considered asymmetric risks to deliver superior rewards. Ahren’s approach empowers founders to achieve ambitious technological advances, contributing significantly to the deep tech startup ecosystem by supporting companies that blend scientific innovation with commercial potential[1][2][3][6].
Ahren Innovation Capital was founded by Alice Newcombe-Ellis alongside co-founding science partners, including notable figures such as Andy Parker, Gregory Winter, and Lord Martin Rees, reflecting a strong scientific and entrepreneurial pedigree. The firm’s origin is rooted in Cambridge’s rich innovation environment, leveraging a partnership model that combines investment talent with best-in-class commercial scientists. This unique blend has allowed Ahren to evolve with a focus on deep science sectors, building a portfolio of companies valued collectively at over $100 billion. Early traction for the firm included investments in high-profile startups in biotechnology and AI, with several successful exits and IPOs that underscore its ability to identify and nurture breakthrough ventures[2][3][4][6].
Ahren Innovation Capital rides the wave of increasing convergence between advanced science and technology, particularly in areas like AI, genetics, and robotics, where breakthroughs can create entirely new markets or disrupt existing ones. The timing is critical as scientific advances accelerate and capital markets become more receptive to deep tech ventures requiring longer development horizons. Market forces such as growing demand for sustainable energy solutions, precision medicine, and AI-driven automation favor Ahren’s investment thesis. By supporting foundational technologies, Ahren influences the broader ecosystem by enabling startups to translate scientific discoveries into scalable commercial products, thus driving innovation and economic growth in high-impact sectors[1][2][3].
Looking ahead, Ahren Innovation Capital is poised to deepen its influence by continuing to back frontier technologies that address global challenges in health, energy, and space exploration. Trends such as AI integration in biotech, advances in genetic engineering, and sustainable energy innovation will shape its portfolio evolution. With over $400 million in dry powder as of 2025, the firm is well-positioned to capitalize on emerging opportunities and support startups through critical growth phases. Its unique blend of scientific expertise and venture capital acumen suggests Ahren will remain a key player in shaping the future of deep tech innovation, helping founders achieve breakthroughs that could define the next generation of technology companies[1][3][6].
Key people at Ahren Innovation Capital.
Ahren Innovation Capital has more than 26 tracked investments across 22 companies. The latest tracked deal is $1.1B Series A in KluraLabs in February 2026.